DELRAY BEACH, Fla., March 25, 2025 /PRNewswire/ -- The US Vaccines Market, (excluding COVID-19 vaccines), valued at US$25.98 billion in 2024, is forecasted to grow at a robust CAGR of 8.2%, reaching an impressive US$38.44 billion by 2029.The growth in the US vaccines market is fueled by various factors such as launch of RSV vaccines, increasing investments by government and non-government organizations for vaccine development and increasing R&D investments by market players.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1155
Browse in-depth TOC on "US Vaccines Market"
151 - Tables
57 - Figures
By Based on technology, the US vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated & subunit vaccines, and other vaccine technologies. In 2023, conjugate vaccine segment dominated the US vaccine market. Rising awareness and preventive healthcare initiatives, increasing pediatric immunization programs, and favorable government & regulatory environments have further bolstered the prominence of conjugated vaccines.
By Based on disease indication, the US vaccines market (excluding COVID-19 vaccines) is segmented into, influenza, combination vaccines, pneumococcal disease, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV and other disease indications. RSV vaccine segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Growing investments in vaccine R&D and novel technologies coupled with high disease burden among infants and older adults has fueled demand for RSV vaccines.
By Based on type, the US vaccines market (excluding COVID-19 vaccines) is segmented into monovalent and multivalent vaccines. Multivalent vaccines segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Advancements in recombinant and conjugate vaccine technologies and increased investment by pharmaceutical companies in R&D for next-generation multivalent vaccines has fueled demand for multivalent vaccines.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1155
The US vaccines market is consolidated, with a small number of players competing for market share. Merck & Co., Inc (US) Pfizer Inc. (US), Emergent (US), Johnson & Johnson Services, Inc (US), Novavax, Inc. (US), Inovio Pharmaceuticals (US), VBI Vaccines (US) and among others are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the US market.
Study Coverage:
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the US vaccines market. The market also covers the impact of the recession. A detailed analysis of the key industry players has been done to provide insights into their business overviews; key strategies; acquisitions, new product launches, expansions, agreements, and recent developments associated with the US vaccines market.
For more information, Inquire Now!
Related Reports:
Cancer Vaccines Market
mRNA Synthesis & Manufacturing Market
Recombinant Proteins Market
Vaccine Adjuvants Market
Veterinary Vaccines Market
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/us-vaccines-market-worth-us38-44-billion-by-2029-with-8-2-cagr--marketsandmarkets-302410253.html
